Drug
Ly4515100 Via Sad
Ly4515100 Via Sad: highest development phase Phase 1, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY4515100 via SAD NCT07339722 | Phase 1 |
Latest
No recent events.
Follow Ly4515100 Via Sad on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.